Get informed when a big investor buys or sells
+ FollowOvervalued by 21.9% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $62.34 Billion |
|---|---|
| Enterprise Value | $65.16 Billion |
| Annual dividend | $1.70 |
| Dividend yield | 0.49% |
| Earnings per Share | $8.2 |
| Beta | 0.2 |
| Outstanding Shares | 190,597,757 |
| P/E Ratio | 25.67 |
|---|---|
| PEG | 18.53 |
| Price to Sales | 3.98 |
| Price to Book Ratio | 5.22 |
| Enterprise Value to Revenue | 4.22 |
| Enterprise Value to EBIT | 14.74 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.31 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized p...